Profound(US:PROF) Globenewswire·2025-12-04 22:00Core Insights - The CAPTAIN trial is the first randomized controlled trial comparing MRI-guided transurethral ultrasound ablation (TULSA) to robotic radical prostatectomy (RP), successfully recruiting to target [1][4] - Dr. Pejman Ghanouni received the Cum Laude award for his presentation on the CAPTAIN trial at the RSNA Annual Meeting, highlighting the significance of the study [1][2] - The TULSA Procedure offers a quicker recovery time compared to robotic RP, with patients feeling better the day after the procedure, while robotic RP patients take nearly three weeks [3] Company Overview - Profound Medical Corp. specializes in AI-powered, MRI-guided, incision-free therapies for tissue ablation, with a focus on the TULSA Procedure [1][5] - The TULSA-PRO system is the only AI-powered, MRI-guided robotic system for prostate therapy, allowing real-time monitoring and personalized treatment [3][6] - Profound is also commercializing Sonalleve, a therapeutic platform for various conditions, including uterine fibroids and bone metastases [7] CAPTAIN Trial Details - The CAPTAIN trial is a multi-center study comparing the safety and efficacy of TULSA with RP in men with organ-confined, intermediate-risk prostate cancer [4] - As of January 2025, 210 patients were randomized, with 69% receiving TULSA and 31% receiving RP, ensuring balanced baseline characteristics [4] - The trial commenced in 2022 across 20 sites in the U.S., two in Canada, and one in Europe, with the last patient treatment occurring in August 2025 [4]